RBC keeps Cytokinetics at sector perform

Cytokinetics, Inc. was maintained at sector perform, speculative risk, by RBC Capital Markets analyst Jason Kantor. The company's lead cardiovascular candidate CK-1827452 is the most important near- and long-term value driver, according to the analyst. RBC believes Cytokinetics will move ispinesib for cancer into a phase 3 combination study. Shares of the South San Francisco, Calif.-based biopharmaceutical company were up 28 cents, or 4.47%, at $6.55 on volume of 467,167 shares versus the three-month running average of 116,028 shares. (Nasdaq: CYTK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.